Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
Jian-wei Chen, Shu-qin Xie Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies...
Saved in:
| Main Authors: | Chen JW, Xie SQ |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2018
|
| Subjects: | |
| Online Access: | https://doaj.org/article/2f923fd7c80f45358b16c470412526a7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial
by: Che T, et al.
Published: (2018) -
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
by: Daniel Cejka
Published: (2021) -
High Unawareness of Chronic Kidney Disease in Germany
by: Susanne Stolpe, et al.
Published: (2021) -
Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
by: Medvedev VE
Published: (2017) -
Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report
by: Igata R, et al.
Published: (2016)